Aim: To evaluate the short term efficacy and safety of monthly intravitreal injections of ranibizumab in patients with polypoidal choroidal vasculopathy (PCV) and active exudation or hemorrhage.
Methods: Prospective, open-label trial of monthly intravitreal ranibizumab (0.5 mg) injections for PCV in 12 eyes of 12 patients. Primary outcome measures were stabilization of vision (loss <15 ETDRS letters). Secondary outcome measures included incidence of ocular and systemic adverse events, and changes in subretinal hemorrhage, central foveal thickness (CFT), and polypoidal complexes on ICG angiography at 6 months.
Results: Baseline findings included 8 eyes with subretinal fluid, 6 eyes with subretinal hemorrhage, and 5 eyes with macular edema (CFT > 275 um). No patient lost > 15 letters in visual acuity at 6 months. Subretinal fluid decreased in 5/8 eyes (63%). Subretinal hemorrhage resolved in 6/6 eyes (100%). Macular edema improved in 4/5 eyes (80%). Polypoidal complexes decreased in 4/12 (33%) eyes. There were no ocular or systemic adverse events.
Conclusions: Continuous monthly intravitreal ranibizumab is safe and well tolerated in eyes with PCV. Preliminary results show stabilization of vision, resolution of subretinal hemorrhage, and decrease in macular edema. Polypoidal lesions decreased in 4/12 (33%) eyes, but branching choroidal vessels persisted.